Etripamil (Cardamyst): A New Era in Acute SVT Management
Etripamil represents the first major pharmacologic innovation for supraventricular tachycardia (SVT) in decades. Approved by the FDA in December 2025, etripamil offers a patient-controlled, intranasal option for the acute termination of paroxysmal supraventricular tachycardia (PSVT) in adults. Its approval marks a paradigm shift from hospital-based intravenous therapy to rapid at-home management.
Background: Why a New SVT Drug Was Needed
Paroxysmal SVT is a common arrhythmia characterized by sudden onset and termination of rapid regular tachycardia, most often due to AV nodal re-entrant tachycardia (AVNRT) or AV re-entrant tachycardia (AVRT).
Traditional acute management includes vagal maneuvers followed by intravenous adenosine or IV calcium channel blockers (verapamil, diltiazem) in the emergency department.
Limitations of existing therapies include:
• Need for IV access and hospital setting
• Significant hypotension with IV CCBs
• Patient anxiety and frequent ER visits
• No approved self-administered acute therapy
Etripamil was developed specifically to address these gaps.
What Is Etripamil?
Etripamil is a Class IV anti-arrhythmic agent belonging to the non-dihydropyridine calcium channel blocker family. Pharmacologically, it is related to verapamil and diltiazem but engineered for ultra-short action and intranasal delivery.
Key pharmacologic characteristics:
• Potent L-type calcium channel blockade
• Predominant effect on the AV node
• Very rapid onset of action
• Extremely short half-life
• Minimal systemic exposure
Mechanism of Action
Etripamil blocks L-type calcium channels within AV nodal tissue, leading to:
• Slowing of AV nodal conduction
• Increased AV nodal refractoriness
• Interruption of re-entrant circuits involving the AV node
This mechanism makes it effective for AV node–dependent PSVT while explaining why it is ineffective and contraindicated in atrial fibrillation, atrial flutter, and ventricular tachycardia.
Route of Administration and Dosing
One of the most transformative aspects of etripamil is its intranasal delivery system.
Dose and use:
• Route: Intranasal spray
• Adult dose: 70 mg per episode
• Administration: One spray in each nostril
• Timing: At onset of PSVT symptoms
• Repeat dosing: Only as specified in prescribing information
Intranasal delivery allows rapid systemic absorption via the nasal mucosa, bypassing first-pass metabolism and eliminating the need for IV access.
Clinical Benefits
Etripamil offers several clinically meaningful advantages:
Self-administration
Patients can treat PSVT episodes at home without immediate medical supervision.
Rapid onset
Designed to terminate PSVT quickly, often within minutes.
Ultra-short duration
Short half-life reduces prolonged hypotension or bradycardia.
Improved safety profile
Lower risk of sustained hypotension compared with IV calcium channel blockers.
Healthcare impact
Potential reduction in emergency department visits and healthcare costs.
Indications
Approved indication:
• Acute termination of paroxysmal supraventricular tachycardia (PSVT) in adults
Most effective in:
• AVNRT
• AVRT involving an accessory pathway with AV node participation
Not Indicated / Not Effective In
Etripamil should not be used in:
• Atrial fibrillation
• Atrial flutter
• Ventricular tachycardia
• Chronic suppression of SVT
Because its action is AV node–dependent, it does not control atrial arrhythmias with chaotic or macro–reentrant atrial activity.
Adverse Effects
Common side effects (usually mild and transient):
• Nasal irritation or discomfort
• Headache
• Facial flushing
• Mild dizziness
• Nausea
Rare but reported adverse effects:
• Transient hypotension
• Palpitations
• Shortness of breath
Due to its short half-life, most adverse effects resolve quickly without intervention.
Contraindications and Precautions
Avoid use in:
• Severe hypotension
• High-grade AV block without a pacemaker
• Known hypersensitivity to calcium channel blockers
Use caution in:
• Patients taking other AV nodal–blocking agents
• Pregnancy and breastfeeding (consult physician)
Patients must be educated to seek emergency care if:
• Symptoms do not resolve
• Diagnosis is uncertain
• Hemodynamic instability develops
Role in Clinical Practice
Etripamil is not a replacement for electrophysiology evaluation or catheter ablation in recurrent SVT, but it fills a critical gap between reassurance and emergency care. It empowers selected patients with a confirmed diagnosis of PSVT to manage acute episodes safely and rapidly.
Its approval represents a shift toward patient-centered arrhythmia care, similar to how self-injectable therapies transformed migraine and anaphylaxis management.
Conclusion
Etripamil (Cardamyst) is the first FDA-approved, self-administered intranasal therapy for acute PSVT. With rapid onset, ultra-short action, and a favorable safety profile, it represents a major advance in SVT management. Proper patient selection, education, and adherence to indications are essential to maximize benefit and ensure safety.
For more cardiology articles and infographics visit:

Comments
Post a Comment
Drop your thoughts here, we would love to hear from you